Shortcut to Body Shortcut to main menu

Invest Korea

Search

Investment News

  • Home
  • Information Center
  • Newsroom
  • Investment News
Sillajen teams up with Regeneron to combat kidney cancer
Date
2017.05.08
Views
1480
According to Pulse by Maeil Business News Korea


South Korea’s biotechnology firm Sillajen, Inc., has teamed up with U.S.-based Regeneron Pharmaceuticals Inc. to co-develop a treatment for kidney cancer.

The drug maker said in a regulatory filing Monday it has signed a deal with Regeneron to test out combination of its oncolytic virus vaccine Pexa-Vec with the U.S. firm’s immune checkpoint inhibitor REGN 2810 in combating renal cell carcinoma.

Under the deal, the two will run a phase 1 clinical trial tests on patients with kidney cancer with the drug cocktail or REGN 2810.

Pexa-Vec is an oncolytic virus vaccine designed to kill cancer cells using the body’s immune system after the patient’s cancer cells are infected with gene-manipulated vaccinia virus. Pexa-Vec infects cancer cells first, and then the patient’s immune system recognizes the infected cancer cells as foreign bodies and attacks them, explained the company.

Regeneron’s REGN-2810 is a programmed cell death protein 1 (PD-1) inhibitor that is being jointly developed by Sanofi and Regeneron.

Shares of Sillajen on Monday rose 1.32 percent to 11,500 won ($10.16) from the previous session.

By Shin Chan-ok

Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.

Source: Pulse by Maeil Business News Korea (May. 8, 2017)


Meta information